<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412319</url>
  </required_header>
  <id_info>
    <org_study_id>SW002</org_study_id>
    <nct_id>NCT02412319</nct_id>
  </id_info>
  <brief_title>The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection</brief_title>
  <official_title>The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shineway Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shineway Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asses the efficacy and safety of the Anti hepatitis B placenta transfer factor injection in&#xD;
      the treatment of HBeAg positive chronic hepatitis B.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study using entecavir tablets as basic therapy, is a randomized, double-blind,&#xD;
      placebo-controlled multi center study, including the screening period (-4 weeks), baseline&#xD;
      and treatment period (96 weeks). The treatment period of first 48 weeks, using entecavir&#xD;
      tablets as basic treatment, placebo-controlled trials; the second 48 weeks, taking entecavir&#xD;
      tablets alone, continue observation experiment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBeAg serum conversion rate</measure>
    <time_frame>Week 48</time_frame>
    <description>The HBeAg serum conversion rate of the Test Group and the Control Group after 48 weeks treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBeAg serum conversion rate</measure>
    <time_frame>Week 24, 72</time_frame>
    <description>The HBeAg serum conversion rate of the Test Group and the Control Group for treatment week 24, week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg disappearance rate</measure>
    <time_frame>Week 24, 48 and 72</time_frame>
    <description>The HBeAg disappearance rate of the Test Group and the Control Group for treatment week 24, week 48 and week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA titer</measure>
    <time_frame>Week-4, 0,12,24,48,72 and 96</time_frame>
    <description>The proportion of subjects for each observation point in HBV DNA titer decreased 2 logarithmic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects for the HBV DNA can not be detected</measure>
    <time_frame>Week 24, 48 and 72</time_frame>
    <description>The proportion of subjects for the HBV DNA can not be detected in treatment week 24, week 48 and week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg and HBsAg titer</measure>
    <time_frame>Week-4, 0,12,24,48,72 and 96</time_frame>
    <description>The changes of HBeAg and HBsAg titer at each observation point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quantitative changes of anti -HBc</measure>
    <time_frame>Week-4, 0,12,24,48,72 and 96</time_frame>
    <description>The quantitative changes of anti -HBc in each observation point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of ALT</measure>
    <time_frame>Week-4,24,48,72 and 96</time_frame>
    <description>The variation of ALT in each observation point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The seroconversion rate of HBsAb and HBeAb</measure>
    <time_frame>Week-4, 0,12,24,48,72 and 96</time_frame>
    <description>The seroconversion rate of HBsAb and HBeAb in each observation point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The resistance mutation rate of HBsAb and HBeAb</measure>
    <time_frame>Week-4, 0,12,24,48,72 and 96</time_frame>
    <description>The resistance mutation ncidence of HBsAb and HBeAb in each observation point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative incidence of virologic breakthroughrate of HBsAb and HBeAb</measure>
    <time_frame>Week-4, 0,12,24,48,72 and 96</time_frame>
    <description>The cumulative incidence of virologic breakthroughrate of HBsAb and HBeAb in each observation point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of relative immune parameters of the transfer factor in peripheral blood(the number of T lymphocytes and the expression levels of cytokines)</measure>
    <time_frame>Week 0, 12, 24, 48, 72, 96</time_frame>
    <description>The changes of relative immune parameters of the transfer factor in peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>HBeAg Positive Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-HBV placenta transfer factor injection</intervention_name>
    <description>Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks</description>
    <arm_group_label>Comparator Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. aged 18-65, sex not limited;&#xD;
&#xD;
          2. patients with HBeAg positive chronic hepatitis B: Screening HBsAg positive for more&#xD;
             than 6 months; screening HBeAg positive; screening serum HBV DNA≥1.0×105U/ml；&#xD;
&#xD;
          3. 2 * ULN (2 times the upper limit of normal value) &lt; ALT &lt;10 * ULN (10 times the upper&#xD;
             limit of normal value);;&#xD;
&#xD;
          4. total bilirubin &lt;51μmol/L;&#xD;
&#xD;
          5. hepatitis B virus resistance gene sequencing negative;&#xD;
&#xD;
          6. agree in the process of the study, do not participate in any other clinical studies or&#xD;
             other anti HBV therapy;&#xD;
&#xD;
          7. before the beginning of the study, understand and sign the informed consent form&#xD;
             approved by the ethics committee, and cooperate to conduct clinical research according&#xD;
             to the requirements for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. by the following evidences prompt suspected hepatocellular carcinoma: B ultrasound or&#xD;
             imaging examination discover occupying lesion;B ultrasound normal but serum alpha&#xD;
             fetoprotein (AFP) level has a continuous increasing trend; AFP &gt; 100ng/ml, and after&#xD;
             review, still so.&#xD;
&#xD;
          2. with liver disease acute exacerbation cause a transient liver function decompensation&#xD;
             disease or baseline with clinical performance of decompensated liver disease;&#xD;
&#xD;
          3. serum creatinine ≥1.5mg/dl (≥130μmol/l);&#xD;
&#xD;
          4. the serum amylase &gt; 2 times the normal reference upper limit value;&#xD;
&#xD;
          5. hemoglobin (male &lt;100g/L, female &lt;90g/L), white blood cell&lt; 3.5* 109/L, platelet&lt; 60 *&#xD;
             109/L;&#xD;
&#xD;
          6. combined with infection of HCV (anti -HCV positive), HIV, anti -HAV IgM positive, anti&#xD;
             -HDV IgM positive, anti -HEV IgM positive, anti -EBV IgM positive, anti -CMV IgM&#xD;
             positive, autoimmune hepatitis(such as the titer of anti nuclear antibody&gt; 1:160) or&#xD;
             activite liver disease caused by other known or unknown reason;&#xD;
&#xD;
          7. investigators consider that may interfere with the treatment,evaluation or compliance&#xD;
             of the subjects, including any uncontrolled clinical significance of kidneys, heart,&#xD;
             lungs, blood vessels, neurogenic, digestive system, metabolic diseases (diabetes,&#xD;
             hyperthyroidism, adrenal disease), immune function disorder or tumor;&#xD;
&#xD;
          8. subjects with a history of alcoholism or drug abuse,investigators consider the&#xD;
             subjects cannot comply with this protocol or affect the results analysis;&#xD;
&#xD;
          9. pregnancy,lactation or female subjects plan to conceive or the companions of male&#xD;
             subjects plan to conceive during the study&#xD;
&#xD;
         10. 6 months before the study medication used immunosuppressants,immunomodulators(thymosin&#xD;
             alpha), cytotoxic drugs;&#xD;
&#xD;
         11. 6 months before the study medication used anti HBV drug therapy (interferon,&#xD;
             Lamivudine, Adefovir, Entecavir and Telbivudine, Tenofovir,etc);&#xD;
&#xD;
         12. plan or have had liver transplantation;&#xD;
&#xD;
         13. received other study drug treatment within 3 months prior to screening;&#xD;
&#xD;
         14. drug allergy history or allergic for Nucleoside or Nucleotide drug;&#xD;
&#xD;
         15. the subjects non compliance with the protocol or subjects exist any situation which&#xD;
             investigators considered not suitable for participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guiqiang Wang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maorong Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>China People's Liberation Army No. Eight One Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zheling Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qingdao Infectious Diseases Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhiqiang zou, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yantai Infectious Diseases Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peili Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Hospital of Qinhuangdao City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dexing Jia, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weifang People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhenghua Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tai'an Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feng Gao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linyi People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sikui Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liaocheng People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>lingdao Huo, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third People's Hospital of Taiyuan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuping Ma, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xi'an Eighth Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hongxu Zhang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luohe Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xu Zhang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Ningxia Medical University</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>April 5, 2015</last_update_submitted>
  <last_update_submitted_qc>April 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBeAg positive chronic hepatitis B</keyword>
  <keyword>HBeAg serum conversion rate</keyword>
  <keyword>HBeAg serum disappearance rate</keyword>
  <keyword>HBeAg and HBsAg titer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

